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Colorectal metastasis to the gallbladder mimicking a primary gallbladder malignancy:
histopathological and molecular characteristics
Aims: Outcomes of colorectal cancer (CRC) treatment
and survival have steadily improved during the past
decades, accompanied by an increased risk of develop-
ing second primary tumours and metastatic tumours
at unusual sites. Metastatic CRC can show mucosal
colonisation, thereby mimicking a second primary
tumour. This potential confusion could lead to incor-
rect diagnosis and consequently inadequate treatment
of the patient. The aim of this study was to differentiate
between metastatic CRC and a second primary (gall-
bladder cancer, GBC) using a combination of standard
histopathology and molecular techniques.
Methods and results: Ten consecutive patients with
both CRC and GBC were identified in our region
using the Dutch National Pathology Archive
(PALGA). Two patients served as negative controls.
Histology of GBC was reviewed by nine pathologists.
A combination of immunohistochemistry, microsatel-
lite analysis, genomewide DNA copy number analysis
and targeted somatic mutation analysis was used to
aid in differential diagnosis. In two patients, CRC and
GBC were clonally related, as confirmed by somatic
mutation analysis. For one case, this was confirmed
by genomewide DNA copy number analysis. How-
ever, in both cases, pathologists initially considered
the GBC as a second primary tumour.
Conclusions: Metastatic CRC displaying mucosal
colonisation is often misinterpreted as a second pri-
mary tumour. A combination of traditional
histopathology and molecular techniques improves
this interpretation, and lowers the risk of inadequate
treatment.
Keywords: clonality, colorectal cancer, gallbladder cancer, metastasis, next-generation sequencing
Introduction
During the past several decades outcomes of cancer
treatment and surveillance have steadily improved, in
particular for colorectal cancer (CRC), due to earlier
diagnosis, more accurate staging techniques and bet-
ter treatment options.1,2 Death rates of CRC in the
United States decreased by half in 2015 (14 per
100 000) compared to 1975 (28 per 100 000).3 One
of the concerns of (long-term) cancer survivorship is
the increased risk of developing a new primary
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tumour, but also metastases in more uncommon
sites. Approximately 25% of CRC patients present
with metastatic disease at presentation (stage IV),
and an additional 18% of patients will develop metas-
tases metachronously after treatment of the primary
CRC.4 Metastatic CRC (mCRC) mainly develops in
liver and lung,5 but rare metastatic sites include, for
example, the small bowel in 0.7%6 of cases and the
gallbladder in 0.8% of cases.6 Especially in these rare
locations, it is important to distinguish metastatic dis-
ease from new primaries, as this is essential for thera-
peutic planning and determining prognosis. The
priority for a primary tumour is early diagnosis fol-
lowed by therapy, mainly surgery with curative
intent, while a metastatic tumour requires a different
approach.
Traditionally, primary tumours are histologically dis-
criminated from metastatic tumours based on the pres-
ence of dysplasia. However, distinguishing primary and
metastatic tumour can occasionally be difficult. Studies
by Shepherd et al.7 and Estrella et al.8 demonstrated
that metastatic gastrointestinal tumours can show sig-
nificant mucosal colonisation, which cannot be distin-
guished from precursor lesions, suggesting that the
presence of dysplasia does not automatically imply a
primary tumour. Other studies have shown this phe-
nomenon in the urinary bladder, lung and liver.9–11
Various additional techniques can help to establish
the origin of a tumour and distinguish primary from
metastatic cancer. Immunohistochemistry (IHC) is
often inconclusive,12 but in the era of next-generation
molecular pathology novel techniques such as
somatic mutation analysis and DNA copy number
analysis have been proven to be valuable tools for
clonality analysis in solid tumours.13
We hypothesised that metastatic spread from CRC
might be unnoticed due to mucosal colonisation, lead-
ing to the incorrect diagnosis of a second primary. We
used a combination of histological and molecular tech-
niques to determine the extent of the problem and
determine diagnostic strategies, using gallbladder cancer
(GBC) as a model.
Patients and Methods
Below is an overall description; additional details on
experimental procedures and (statistical) analyses are
provided as online Data S1.
P A T I E N T S E L E C T I O N
Patients were identified using a search question (LZV-
1152) in the PALGA-database (the nationwide
network and registry of histo- and cytopathology in
the Netherlands).14 We combined patient data from
the Radboud University Medical Center (UMC) (Nij-
megen), Rijnstate (Arnhem) and Jeroen Bosch (’s-Her-
togenbosch) hospitals to select patients with both
GBC and CRC. In the period between 1989 and 2015
we identified 10 consecutive patients with both
tumours, two of which served as negative controls for
the current study: the first patient developed a pri-
mary GBC 5 years before the CRC and the second
patient presented with a neuroendocrine carcinoma
of the colon with a simultaneous gallbladder adeno-
carcinoma.
Information on gender, age at time of diagnosis
and location of the CRC and GBC were collected ret-
rospectively via review of the pathology report and
medical history. This study was approved by the Rad-
boud UMC medical ethics committee (2014/306).
H I S T O L O G I C A L E X A M I N A T I O N
Tumour blocks were selected based on the pathology
reports and review of histology. One haematoxylin-
and eosin (H&E)-stained slide of the gallbladder of
each patient was analysed by nine independent
pathologists: six non-academic pathologists of the Jer-
oen Bosch Hospital and three academic pathologists
of the Radboud UMC. Histological typing was per-
formed using the World Health Organisation (WHO)
histological classification of tumours of the gallblad-
der and extrahepatic bile ducts.15 T-classification for
CRC and GBC was performed using the American
Joint Committee on Cancer (AJCC) tumour–node–
metastasis (TNM) classification system (7th edn).16
Furthermore, slides were assessed on the presence of
dysplasia and pathologists were asked if the gallblad-
der tumour should be considered a primary or meta-
static tumour based on histology. Presence or
absence of dysplasia and primary/metastasis were
indicated when more than half of the pathologists
agreed.
I M M U N O H I S T O C H E M I S T R Y (IHC)
IHC was performed on 4 µm formalin-fixed paraffin-em-
bedded (FFPE) tissue sections of CRC and GBC with
standard chromogenic horseradish peroxidase-di-
aminobenzidine (HRP-DAB) detection method
(Table S1). CK7/CK20/CDX2/SATB2 staining was
applied and immunoexpression examined as negative,
weak (weak intensity/limited cells) and strong (strong
intensity/extensive positive cells). MMR protein staining
was scored as described previously.17 Two independent
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observers (N.K., I.N.) evaluated all sections. Inconsisten-
cies in scoring were re-evaluated to obtain agreement.
M O L E C U L A R A N A L Y S E S
For microsatellite, mutation and copy number analy-
sis, DNA was isolated from FFPE-derived CRC and
GBC and matched normal colon tissue, as described
previously.18 Microsatellite analysis was performed
with a pentaplex polymerase chain reaction (PCR) for
five quasimonomorphic mononucleotide markers.
For mutation analysis, the single-molecule Molecu-
lar Inversion Probe (smMIP) target enrichment tech-
nology18 was used. Two custom gene panels
(Table S2) were designed using the MIPgen pipe-
line.19 SmMIP library preparations were performed
manually, in essence as described previously.18 BCL
to FASTQ conversion and de-multiplexing of barcoded
reads was performed at the Radboud UMC Genomics
Technology Center. Mapping of reads to the reference
genome and consensus read building was performed
with SeqNext software from JSI medical systems (ver-
sion 4.3.0, build 505; JSI Medical Systems, Etten-
heim, Germany). Specific settings and variant filtering
strategy are provided in Figure S1.
Shallow whole genome sequencing for copy num-
ber analysis was performed at The Tumour Genome
Analysis Core, Department of Pathology, Amsterdam
UMC, Vrije Universiteit Amsterdam, Cancer Center
Amsterdam, as described previously.20 In short,
approximately 10 million SR50 sequence reads were
generated on the Illumina HiSeq 2500 sequencing
platform. Sequence reads were aligned to the refer-
ence genome (GRCh37/hg19) with BWA (version
0.5.9) and downstream analyses were performed with
R-packages QDNAseq20 and DNAcopy.21
S T A T I S T I C A L A N A L Y S E S
Clonality analysis was based on somatic mutations
and DNA copy number aberrations. For somatic
mutations, a statistical test strategy developed by
Ostrovnaya et al. was used.22 DNA copy number
profiles were statistically compared using Pearson’s
correlation and the log-likelihood ratio measure, also
developed by Ostrovnaya et al.23
Results
P A T I E N T A N D T U M O U R C H A R A C T E R I S T I C S
Patient and tumour characteristics and results of
IHC/MSI analysis are shown in Table 1. In total,
eight cases with both a GBC and CRC and two con-
trols were selected. Control 1 developed a GBC before
developing a CRC and control 2 had a neuroen-
docrine CRC together with a gallbladder adenocarci-
noma. In five patients the diagnosis of CRC and GBC
was synchronous. Three patients had a history of
CRC and developed GBC in an average time of
4 years. All CRCs were classified as adenocarcinoma
not otherwise specified, except for control 2 (neuroen-
docrine carcinoma). Dysplasia in the gallbladder was
observed in both negative controls and in six of eight
cases (Figure 1A), and correlated with the suggested
diagnosis of primary GBC based on histological evalu-
ation (Figure 1B). In two cases (2 and 7), patholo-
gists suspected mCRC to the gallbladder (Figure 1B),
and no dysplasia was observed.
Examples of gallbladder dysplasia are shown in Fig-
ure 1C (case 1), 1D (case 3) and 1E (control 1). Fig-
ure 1F shows intestinal metaplasia of the gallbladder
(control 1).
I M M U N O H I S T O C H E M I C A L R E S U L T S A N D M S I
S T A T U S
Three of the cases showed a concordant CK7/CK20/
CDX2/SATB2 profile in both CRC and GBC (Table 1),
whereas the other five cases and both controls
showed a discordant pattern (Table 1 and Figure 2).
In one patient (case 7), both CRCs showed microsatel-
lite instability (MSI), with loss of MLH1 and PMS2
expression. The GBC also showed loss of PMS2
expression, but MSI could not be demonstrated by
pentaplex PCR. Other cases were microsatellite stable
(MSS).
D N A C O P Y N U M B E R P R O F I L E S
All DNA copy number profiles were first inspected
visually, expected and observed noise were calculated,
and gender was checked. All profiles were of high
quality, as shown by the small difference between the
observed and the expected ratio. All the genders, as
observed in the data, matched the annotation in the
patient records.
The detection of numerical chromosomal copy num-
ber aberrations was limited for a few of the samples.
The small number of aberrations detected decreased
their interpretation, such that for case 1 both CRC and
GBC and case 7 no clonality score could be made based
on CNA profiling (Figure 5, Figure S2).
Profiles were compared with Pearson’s correlation
and subsequent hierarchical clustering of the correla-
tion matrix. This showed that the CRC and GBC of
© 2019 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 75, 394–404.
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patient 3 were highly similar, suggestive of clonality
(Figure 3). Furthermore, we observed clustering of
the biopsy and resection of the CRC of case 2 as a
validation which serves as an attractive internal con-
trol in this analysis. Clonal relatedness was also eval-
uated with a log-likelihood ratio measure, confirming
clonality in case 3 [log2(LR2) = 36.27; P < 0.0001].
M U T A T I O N P R O F I L E S
DNA quality was insufficient for somatic mutation
and clonality analysis in three patients (cases 2
and 5 and control 1). In two cases (1 and 3), all
mutations were shared between the CRC and GBC
(Figure 4) and tumours were clonally related
(P < 0.0001). In the other cases (4, 6, 7 and 8),
and in control 2, tumours did not share
identical mutations and were not clonally
related.
An overview of all findings is shown in Figure 5.
In cases 1 and 3, clonal relatedness of both tumours
was supported by a combination of concordant IHC,
DNA copy number and DNA mutation profiles. In
contrast, based on histology, they were regarded as
independent primary tumours. Although a concor-
dant IHC profile was observed in case 8, tumours
were presumed unrelated, indicated by histological
and clonality analyses.
Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8
Control 1
Control 2
Dysplasia yes Dysplasia no
Pathologist
Academic pathologist
Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8
Control 1
Control 2
Primary yes Primary no
A
B
Pathologist
Academic pathologist
1000 µm
C
D
500 µm
1000 µm
E
F
500 µm
Figure 1. Review results of
histopathology of gallbladder
cancers (GBCs) of eight cases
and two controls (not all
features were examined by
each pathologist). A, Presence
of dysplasia; B, primary GBC or
metastatic CRC; C–E, dysplasia
in the gallbladder; Country,
case 1; D, case 3; E, control 1;
F, intestinal metaplasia in the
gallbladder (control 1).
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Discussion and Conclusion
In a consecutive series, we describe two patients with
metastatic spread of CRC to the gallbladder. Based on
histopathological similarity to primary GBC, these
cases would have gone unnoticed and patients would
not have received the optimal treatment.
Metastases to the gallbladder are considered
uncommon, and usually manifest as end-stage of
malignancy. Two large autopsy studies reported gall-
bladder involvement in 2.2–5.8% of all cancer
patients,6,24 but both studies are dated and it is
unclear whether these metastases were part of wide-
spread metastatic disease. One more recent imaging
study, although not comparable in study size, con-
firmed that isolated metastasis to the gallbladder is
rare.25 CRC metastasising to the gallbladder seems
almost non-existent, with only a few case reports in
the English literature.26–29 Metastases of other pri-
mary cancer types to the gallbladder, such as mela-
noma or renal cell carcinoma, are more frequently
observed, presumably because of their distinct histo-
logical features.30,31
Diagnostic confusion may arise because of mucosal
colonisation by mCRC, i.e. growth along an intact
basement membrane and colonisation of the existing
epithelium, thereby mimicking a primary tumour. We
also observed this phenomenon in case 3 (Figure 1D),
where the GBC was initially considered a primary
tumour. Mucosal colonisation has been described pre-
viously in lung,10 liver11 and urinary bladder,9 and
seems more frequent in tumours originating from the
Case 4 GBC
Scale:200 µm
H
&E
CK
7
CK
20
CD
X2
SA
TB
2
Case 4 CRC Case 6 CRCCase 6 GBC
Figure 2. Immunohistochemical staining for cases 4 and 6. Case 4 showed discordance for SATB2 between gallbladder cancer (GBC) and
colorectal cancer (CRC), whereas case 6 showed discordance for CK7, CDX2 and SATB2 between GBC and CRC. H&E, haematoxylin and
eosin; CK7, cytokeratin 7; CK20, cytokeratin 20; CDX2, caudal type homeobox 2; SATB, homeobox 2.
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GI tract.8 The mechanisms underlying mucosal
colonisation are largely unknown. Perhaps it is the
result of dynamic conversion of the epithelial–mes-
enchymal transition (EMT) required for migration
and invasiveness of metastatic cells to mesenchymal–
epithelial transition (MET) required for the cells to
colonise their target site. Spatiotemporal regulation of
EMT-MET involves widespread reprogramming of
gene expression by epigenetic and transcriptional reg-
ulators,32 and by microRNAs that regulate gene
expression on post-transcriptional level,33 both influ-
enced by the tumour microenvironment.34,35
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Figure 3. Correlation matrix of genome-wide copy number data, hierarchically clustered. Colorectal cancer (CRC) and gallbladder cancer
(GBC) of case 3 cluster together, as well as the biopsy and resection specimen of CRC of case 2. Case 7: CRC-1, caecum; CRC-2, hepatic
flexure.
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Significant differential expression of microRNAs was
observed in cancer cells cultured on matrigel base-
ment membrane matrix, i.e. the in-vitro substitute of
a basal membrane, and on plastic.36
To differentiate mCRC from primary GBC, a panel
of CK7, CK20, CDX2 and SATB2 IHC stains was
used. CRC predominantly displays a CK7–/CK20+
immunophenotype (65.8% of cases),37 whereas GBC
typically displays a CK7+/CK20– immunophenotype
(47.6% of cases).38 CDX2 immunoreactivity has been
observed in 72–100% of CRCs39–41 and in 36–45%
of GBCs.42,43 To our knowledge, there are no studies
that specifically investigated the expression of SATB2
in primary GBC. In addition, gallbladders may display
primary intestinal-type adenocarcinoma and may also
have intestinal metaplasia (Figure 1F), one of the pre-
cursor lesions of GBC, observed in 12–85% of
cases,44–49 which limits the usefulness of these IHC
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Figure 4. Summary of mutation and clonality analysis. For cases 2 and 5 and control 1, mutation analysis failed/was not performed because
of insufficient DNA quantity and quality. In cases 1 and 3, identical mutations were present both in colorectal cancer (CRC) and gallbladder
cancer (GBC) (green fill) and tumours were clonally related P < 0.0001. In the other cases and in control 2, mutations were exclusively pre-
sent in either CRC (yellow fill) or GBC (blue fill) and tumours were unrelated. *Confirmed retrospectively in CRC, with coverage lower than
threshold of >5 mut. reads and 5% mut. reads. As this variant was also identified in a diagnostic setting using an Ion Torrent platform with
40% mut. allele, it was included in clonality analysis. [Colour figure can be viewed at wileyonlinelibrary.com]
Patient
Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8
Control 1
Control 2
  
Histology IHC profile MSI status DNA copy
number
Mutation
analysis(CK7/CK20/CDX2/SATB2) (IHC/MSI assay)
Figure 5. Summary of findings.
Green fill, suspected
metastasis/clonally related
(concordance); red fill,
suspected primary
(discordance); grey fill, not
assessable. [Colour figure can
be viewed at wileyonlinelibra
ry.com]
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markers. In cases 1 and 3, concordant IHC profiles
supported that tumours were clonally related.
Recent advances in molecular pathology are of
great value in studying the molecular origin of a
tumour. Microsatellite analysis, for example, was suc-
cessfully applied in other studies50,51 to determine the
origin of synchronous and metachronous tumours
from various organs. In this study, however,
microsatellite analysis was less informative, as only
one patient showed MSI in both CRCs. The GBC of
the same case was MSS, suggesting that tumours
were unrelated. With somatic mutation and clonality
analysis, we concluded that the CRC and GBC of
patients 1 and 3 were clonally related. Genes with
shared variants included APC, ERBB3, KRAS,
PIK3CA, SOX9 and TP53. Unfortunately, the amount
and quality of the input DNA was limited. All DNA
was derived from FFPE tissue, most was relatively old
and some derived from biopsy material, significantly
decreasing the quality and yield. DNA copy number
analysis supported that both tumours of patient 3
were clonally related. For a few of the samples, low
numbers of numerical chromosomal copy number
aberrations were detected, limiting their interpreta-
tion. This could either be the result of lower tumour
cell percentages than estimated or of intratumoural
heterogeneity with subclonal copy number aberra-
tions.
Discriminating primary from metastatic cancer is
essential for adequate therapeutic planning and prog-
nosis of the patient, as misdiagnosis will result in sub-
optimal treatment with detrimental consequences.
Both timing and choice of chemotherapy treatment
differ in CRC and GBC. Furthermore, evidence on the
efficacy of adjuvant chemotherapy in GBC is lim-
ited.52 Chemotherapy is only indicated in unre-
sectable and metastatic GBC, with gemcitabine and
cisplatin (GemCis).53,54 For unresectable mCRC, how-
ever, first-line treatment involves a fluoropyrimidine
(5-fluorouracil or capecitabine), alone or in combina-
tion with a targeted therapy, in various combinations
and schedules.55 A few small studies were performed
in GBC using fluoropyrimidine-based chemotherapeu-
tics,56,57 but schedules differed considerably from
those used for CRC. In addition, GemCis treatment
has not been widely investigated in (metastatic) CRC.
Only a few studies have investigated the benefit of
gemcitabine combined with 5-fluorouracil as second-
or third-line therapy in a palliative setting with
refractory CRC,58,59 but not in combination with cis-
platin. Proper distinction of mCRC and primary GBC
is therefore essential to select appropriate treatment.
In conclusion, we described two patients with
metastatic spread of CRC to the gallbladder in a con-
secutive series of eight patients and two controls with
a CRC and a GBC. The majority of these GBCs were
considered primary tumours based on the presence of
dysplasia. As histological assessment alone is not suf-
ficient for differential diagnosis, we recommend for all
cases initial testing with immunohistochemistry,
although this is of limited use when the stains are
concordant. Molecular analyses are necessary in
those cases to confirm clonal relations, which is
imperative for an accurate diagnosis and optimal
treatment.
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